Results 221 to 230 of about 18,378,232 (237)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial [PDF]
BACKGROUND Clinical decompensation of cirrhosis is associated with poor prognosis. Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure gradient (HVPG) ≥10 mm Hg, is the strongest predictor of decompensation.
Rosa Maria Morillas +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:

